Literature DB >> 24477329

Pathogenesis and clinical features of chronic pulmonary aspergillosis - is it possible to distinguish CNPA and CCPA clinically?

Koichi Izumikawa1, Takayoshi Tashiro2, Masato Tashiro3, Takahiro Takazono3, Kosuke Kosai3, Yoshitomo Morinaga4, Shintaro Kurihara3, Shigeki Nakamura3, Yoshifumi Imamura3, Taiga Miyazaki3, Misuzu Tsukamoto3, Hiroshi Kakeya3, Tomayoshi Hayashi5, Katsunori Yanagihara4, Takeshi Nagayasu6, Shigeru Kohno3.   

Abstract

BACKGROUND: The pathogenesis of chronic pulmonary aspergillosis (CPA) including chronic necrotizing pulmonary aspergillosis (CNPA), chronic cavitary pulmonary aspergillosis (CCPA), and simple aspergilloma (SA) has been poorly investigated. We examined all types of CPA cases with histopathological evidence to clarify the differences in pathogenesis and clinical features.
METHOD: We searched for cases diagnosed as pulmonary aspergillosis by histopathological examination in Nagasaki University Hospital between 1964 and September 2010. All available clinical information including radiological findings were collected and analyzed. RESULT: We found 7, 5, 8, and 7 cases of proven CNPA, probable CNPA, CCPA, and SA, respectively. The radiograph of proven and probable CNPA was initially infiltrates or nodules that progress to form cavities with or without aspergilloma, whereas the radiograph of CCPA showed pre-existed cavities and peri-cavitary infiltrates with or without aspergilloma. The patients with proven and probable CNPA exhibited not only respiratory symptoms but also systemic symptoms and malnutrition. Aspergillus fumigatus was the most frequently isolated Aspergillus species (n = 14), however, Aspergillus niger was the predominant isolated species in proven CNPA cases (n = 4).
CONCLUSION: Our data indicate that the cases with chronic infiltration, progressive cavitation, and subsequent aspergilloma formation should be diagnosed as CNPA, and the cases with pre-existed cavities showing peri-cavitary infiltrates with or without aspergilloma would mean CCPA. However, it may be difficult to distinguish the two subtypes if a series of adequate radiography films are not available. We propose the term "chronic progressive pulmonary aspergillosis (CPPA)" for the clinical syndrome including both CNPA and CCPA.
Copyright © 2013 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic cavitary pulmonary aspergillosis; Chronic necrotizing pulmonary aspergillosis; Chronic progressive pulmonary aspergillosis

Mesh:

Year:  2013        PMID: 24477329     DOI: 10.1016/j.jiac.2013.10.016

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  12 in total

1.  Evaluation of the Aspergillus Western blot IgG kit for diagnosis of chronic aspergillosis.

Authors:  A Oliva; P Flori; C Hennequin; J-C Dubus; M Reynaud-Gaubert; D Charpin; J M Vergnon; P Gay; A Colly; R Piarroux; H Pelloux; S Ranque
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

2.  Usefulness of Two Aspergillus PCR Assays and Aspergillus Galactomannan and β-d-Glucan Testing of Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis.

Authors:  Naohisa Urabe; Susumu Sakamoto; Go Sano; Junko Suzuki; Akira Hebisawa; Yasuhiko Nakamura; Kazuya Koyama; Yoshikazu Ishii; Kazuhiro Tateda; Sakae Homma
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

3.  Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series.

Authors:  G Cucchetto; A Cazzadori; M Conti; G L Cascio; P Braggio; E Concia
Journal:  Infection       Date:  2014-11-29       Impact factor: 3.553

4.  Monaldi cavernostomy for lung aspergillosis: A case report.

Authors:  Cornel Petreanu; Alina Croitoru; Alexandru Gibu; Alexandru Zariosu; Nicolae Bacalbasa; Irina Balescu; Camelia Diaconu; Ovidiu Stiru; Mihai Dimitriu; Dragos Cretoiu; Cornel Savu
Journal:  Exp Ther Med       Date:  2021-07-06       Impact factor: 2.447

5.  The scab-like sign: A CT finding indicative of haemoptysis in patients with chronic pulmonary aspergillosis?

Authors:  Haruka Sato; Fumito Okada; Shunro Matsumoto; Hiromu Mori; Junji Kashiwagi; Eiji Komatsu; Toru Maeda; Haruto Nishida; Tsutomu Daa; Satoshi Ohtani; Kenji Umeki; Masaru Ando; Junichi Kadota
Journal:  Eur Radiol       Date:  2018-05-03       Impact factor: 7.034

6.  Histological study of chronic pulmonary aspergillosis.

Authors:  Naobumi Tochigi; Takao Ishiwatari; Yoichiro Okubo; Tsunehiro Ando; Minoru Shinozaki; Kyoko Aki; Kyoko Gocho; Yoshinobu Hata; Somay Y Murayama; Megumi Wakayama; Tetsuo Nemoto; Yasuhiro Hori; Kazutoshi Shibuya
Journal:  Diagn Pathol       Date:  2015-09-03       Impact factor: 2.644

7.  A case of treatment with voriconazole for chronic progressive pulmonary aspergillosis in a patient receiving tacrolimus for dermatomyositis-associated interstitial lung disease.

Authors:  Eisuke Mochizuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Naoki Inui; Yutaro Nakamura; Masato Kono; Etsuko Hamada; Masato Maekawa; Takafumi Suda
Journal:  Respir Med Case Rep       Date:  2015-11-03

8.  Hemoptysis due to fungus ball after tuberculosis: A series of 21 cases treated with hemostatic radiotherapy.

Authors:  Lucas G Sapienza; Maria José L Gomes; Carmelindo Maliska; Antonio N Norberg
Journal:  BMC Infect Dis       Date:  2015-11-26       Impact factor: 3.090

Review 9.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07

Review 10.  Pulmonary Mycobacterium parascrofulaceum Infection in a Patient with Chronic Progressive Pulmonary Aspergillosis: A Case Report and Literature Review.

Authors:  Hiroaki Ikegami; Kei Yamasaki; Toshinori Kawanami; Kazumasa Fukuda; Kentaro Akata; Midori Nakamura; Issei Ikushima; Yoko Fukuda; Shingo Noguchi; Kazuhiro Yatera
Journal:  Intern Med       Date:  2019-12-20       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.